Homepage > Company > Media > Pharma News > 2024 > Bayer and MOMA Therapeutics partner for oncology programme

Bayer and MOMA Therapeutics partner for oncology programme

Bayer has entered a strategic collaboration with MOMA Therapeutics to advance a small molecule oncology programme, leveraging the latter’s KNOMATIC platform.

The partnership aims to target dynamic proteins, a novel class of therapeutic targets in cancer treatment. Under the terms of the option and exclusive licence agreement, Bayer will oversee the programme’s progression through further preclinical development and potential commercialisation.

The collaboration grants Bayer access to the programme and to the results generated from KNOMATIC platform. The platform combines structural insights, advanced hit-finding technologies and computational lead optimisation to speed up the discovery of therapeutics that effectively target dynamic proteins.

These proteins are pivotal in disease progression and represent an underexplored opportunity for creating novel cancer therapies through a small molecule approach.

MOMA is entitled to receive an upfront payment as well as a collaboration fee from Bayer. Bayer could pay additional payments on MOMA achieving specific discovery, development and commercial milestones. The agreement also includes tiered royalty payments on net product sales for MOMA. The companies did not disclose the financial details of the collaboration.

In August 2024, Bayer teamed up with startup biotech NextRNA Therapeutics to develop small molecules targeting long non-coding RNAs (lncRNAs) in oncology.

Read also

Sunvozertinib Granted Breakthrough Therapy Designation by China CDE for the First-Line Treatment of Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Dizal, a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that the Center for Drug Evaluation (CDE) of China&...

FDA Approves Marstacimab-hncq for Adults, Adolescents With Hemophilia A or B Without Inhibitors

This approval marks the first and only anti-tissue factor pathway inhibitor approved in the US for the treatment hemophilia A or B, and the first approved hemophilia treatment to be administered via a...

Gilead gives up on $15M MASH bet with Yuhan after mulling preclinical data

In a year that has seen an approval and a raft of readouts for metabolic dysfunction-associated steatohepatitis (MASH), Gilead has decided to walk away from a $785 million biobucks deal in the...

FDA AdCom votes in favour of Stealth’s Barth syndrome drug

AUS Food and Drug Administration (FDA) advisory committee (AdCom) has voted in support of Stealth BioTherapeutics’ first-line Barth syndrome drug, despite a trial studying the drug n...